Infectious Disease Clinical Trials

Statistical methods in infectious disease trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All infectious disease trials

903 results

• Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 3Results postedn = 114NCT04673214
• Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05011513).Phase 2/3Results postedn = 1,440NCT05011513
• Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02067039).Phase NAResults postedn = 2,665NCT02067039
• Evaluation of Reactogenicity and Safety of GSK Biologicals’ Rotarix™ (Human Rotavirus Vaccine) in Infants: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 522NCT00779779
• Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 873NCT01031069
• Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 989NCT02075203
• Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants: primary endpoint results, effect estimate with confidence interval,…Phase 1Results postedn = 8NCT01700179
• Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 234NCT05322473
• Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2Results postedn = 365NCT01785186
• Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 33NCT03186378
• Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 66NCT02687529
• Evaluation of the Antimicrobial Effectiveness of CHG/IPA: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Antimicrobial Effectiveness of CHG/IPA: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04035161).Phase NAResults postedn = 1,935NCT04035161
• Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 47,208NCT00709891
• Evaluation of the Efficacy and Safety of a Loop Stretchable Dental Floss: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Efficacy and Safety of a Loop Stretchable Dental Floss: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 64NCT06515483
• Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals’ HPV Vaccine in Healthy Indian Women: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 354NCT00344032
• Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058): Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 150NCT03843632
• Evaluation of the Implementation and Effectiveness of IPP-HPV: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Implementation and Effectiveness of IPP-HPV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02994290).Phase NAResults postedn = 817NCT02994290
• Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 30NCT01943110
• Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 330NCT05817045
• Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of the Safety and Immune Responses of the Towne Strain of CMV in Seronegative Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2/3Results postedn = 82NCT00201448
• EVOGUARDIndependent statistical analysis of Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 1,892NCT04553068
• EW-DIndependent statistical analysis of A Community Wellness Program for Adults Living With Long-term Physical Disability: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 516NCT03653390
• Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 8NCT02530515
• Examining How a Text Message-based Educational Intervention Influences COVID-19 Testing: Complete Statistical AnalysisIndependent statistical analysis of Examining How a Text Message-based Educational Intervention Influences COVID-19 Testing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT07074171).Phase NAResults postedn = 384NCT07074171
• Experiential HIV Testing Increasing Testing Related Knowledge and Practice, and Reduce Stigma Toward HIV of Nurses.: Complete Statistical AnalysisIndependent statistical analysis of Experiential HIV Testing Increasing Testing Related Knowledge and Practice, and Reduce Stigma Toward HIV of Nurses.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 74NCT05615935
• Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies: Complete Statistical AnalysisIndependent statistical analysis of Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 1Results postedn = 12NCT04893239
• Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 51NCT01438996
• Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection: Complete Statistical AnalysisIndependent statistical analysis of Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection: primary endpoint results, effect estimate with confidence interval, sample-size…Phase 2Results postedn = 12NCT02738008
• Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.: Complete Statistical AnalysisIndependent statistical analysis of Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.: primary endpoint results, effect estimate with confidence interval,…Phase 2Results postedn = 80NCT02690181
• EXTRA-CVDIndependent statistical analysis of A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 298NCT03643705
• Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation: Complete Statistical AnalysisIndependent statistical analysis of Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04683744).Phase NAResults postedn = 82NCT04683744
• FACTS 001Independent statistical analysis of FACTS 001, a randomized phase 3 trial evaluating tenofovir gel for prevention of HIV-1 infection in women and effects on HSV-2 infection.Phase 3n = 2,059NCT01386294
• Feasibility of SBIRT-PN: Complete Statistical AnalysisIndependent statistical analysis of Feasibility of SBIRT-PN: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03057119).Phase NAResults postedn = 86NCT03057119
• Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV: Complete Statistical AnalysisIndependent statistical analysis of Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 48NCT04193605
• Feasibility Study of GlaxoSmithKline Biologicals’ GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.: Complete Statistical AnalysisIndependent statistical analysis of Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 16NCT00871741
• Fecal Microbiota Transplantation (FMT) for MDRO UTI: Complete Statistical AnalysisIndependent statistical analysis of Fecal Microbiota Transplantation (FMT) for MDRO UTI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03367910).Phase 1/2Results postedn = 1NCT03367910
• FEM-PrEPIndependent statistical analysis of FEM-PrEP, a randomized phase 3 trial evaluating Truvada versus placebo for preventing HIV acquisition in women, including its time-to-event analysis, safety endpoints, secondary outcomes, and statistical interpretation.Phase 3Results postedn = 2,120NCT00625404
• Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense: Complete Statistical AnalysisIndependent statistical analysis of Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03974178).Phase 2/3Results postedn = 45NCT03974178
• First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.: Complete Statistical AnalysisIndependent statistical analysis of First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.: primary endpoint results, effect estimate with…Phase 1Results postedn = 26NCT04535167
• First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1Results postedn = 88NCT03261401
• First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants: Complete Statistical AnalysisIndependent statistical analysis of First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1Results postedn = 73NCT05163522
• Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight: Complete Statistical AnalysisIndependent statistical analysis of Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 362NCT00734539
• Fluid Balance in the ICU – Interventions to Minimize Fluids in Patients With Septic Shock: Complete Statistical AnalysisIndependent statistical analysis of Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 82NCT02473718
• FOCUSComplete statistical analysis of the FOCUS randomized phase 3 trial comparing liberal and restrictive blood transfusion strategies in surgical patients with cardiovascular disease, including endpoint definitions, reported odds ratios and risk differences,…Phase 3Results postedn = 2,016NCT00071032
• FREESIAIndependent statistical analysis of Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV): primary endpoint results, effect…Phase 2Results postedn = 3NCT04056611
• From Innovation to Solutions: Childhood Influenza Vaccination Planning: Complete Statistical AnalysisIndependent statistical analysis of From Innovation to Solutions: Childhood Influenza Vaccination Planning: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01664793).Phase NAResults postedn = 87,665NCT01664793
• FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir: Complete Statistical AnalysisIndependent statistical analysis of FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 38NCT01777997
• Fucidin® Cream in the Treatment of Impetigo: Complete Statistical AnalysisIndependent statistical analysis of Fucidin® Cream in the Treatment of Impetigo: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00986856).Phase 4Results postedn = 58NCT00986856
• G2YMIIndependent statistical analysis of Getting to Yes, Michigan! (G2YMI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05096260).Phase NAResults postedn = 1,180NCT05096260
• GAINIndependent statistical analysis of Improving HIV Diagnosis, Linkage to Care, and Prevention Services With HIV Point-of-Care Nucleic Acid Tests: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 194NCT04880200

← All therapeutic areas